|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,080.00 JPY | -0.14% |
|
+5.07% | +5.07% |
| 01-08 | Halozyme Therapeutics, Takeda Collaborate on Vedolizumab Drug Delivery | MT |
| 01-06 | Nimbus, Lilly sign deal to develop new oral obesity drug | RE |
Business description: Takeda Pharmaceutical Company Limited
Number of employees: 47,455
Sales by Activity: Takeda Pharmaceutical Company Limited
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
Pharmaceutical Products | 3,198B | 3,569B | 4,027B | 4,264B | 4,582B |
Geographical breakdown of sales: Takeda Pharmaceutical Company Limited
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
United States | 1,568B | 1,714B | 2,104B | 2,196B | 2,380B |
Europe and Canada | 666B | 739B | 843B | 967B | 1,055B |
Japan | 560B | 659B | 512B | 451B | 418B |
Latin America | 122B | 128B | 160B | 198B | 236B |
China | - | - | - | - | 192B |
Other | 68.52B | 68.94B | 95.18B | 118B | 129B |
Asia (Excluding Japan & China) | - | - | - | - | 99.39B |
Russia/CIS | 57.56B | 62.06B | 88.43B | 72.59B | 72.36B |
Asia (Excluding Japan) | 156B | 197B | 225B | 261B | - |
Executive Committee: Takeda Pharmaceutical Company Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 59 | 2015-03-31 |
Milano Furuta
DFI | Director of Finance/CFO | - | 2024-03-31 |
Mwana Lugogo
CMP | Compliance Officer | 56 | 2011-12-31 |
Norimasa Takeda
CMP | Compliance Officer | - | - |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 2022-01-31 |
Composition of the Board of Directors: Takeda Pharmaceutical Company Limited
| Director | Title | Age | Since |
|---|---|---|---|
Christophe Weber
BRD | Director/Board Member | 59 | 2014-05-31 |
Andrew Plump
BRD | Director/Board Member | 60 | 2015-05-31 |
| Director/Board Member | 73 | 2016-05-31 | |
Emiko Higashi
BRD | Director/Board Member | 66 | 2016-05-31 |
Michel Orsinger
BRD | Director/Board Member | 68 | 2016-05-31 |
Jean-Luc Butel
BRD | Director/Board Member | 68 | 2016-05-31 |
Koji Hatsukawa
BRD | Director/Board Member | 74 | 2016-05-31 |
Ian Clark
BRD | Director/Board Member | 64 | 2018-12-31 |
Steven Gillis
BRD | Director/Board Member | 72 | 2018-12-31 |
Masami Iijima
CHM | Chairman | 75 | 2022-05-31 |
Holdings: Takeda Pharmaceutical Company Limited
| Name | Equities | % | Valuation |
|---|---|---|---|
| 23,558,168 | 1.48% | 729 M $ | |
| 24,307,322 | 6.51% | 163 M $ | |
| 2,204,840 | 7.67% | 29 M $ | |
OVID THERAPEUTICS INC. 12.33% | 8,781,996 | 12.33% | 14 M $ |
CHORDIA THERAPEUTICS INC. 15.33% | 10,760,500 | 15.33% | 7 M $ |
NOILE-IMMUNE BIOTECH INC. 18.76% | 8,119,800 | 18.76% | 7 M $ |
| 1,824,977 | 3% | 3 M $ | |
SHATTUCK LABS, INC. 0.81% | 515,619 | 0.81% | 2 M $ |
LYELL IMMUNOPHARMA, INC. 0.26% | 54,887 | 0.26% | 2 M $ |
XILIO THERAPEUTICS, INC. 2.81% | 1,475,121 | 2.81% | 944 077 $ |
Company details: Takeda Pharmaceutical Company Limited
Group companies: Takeda Pharmaceutical Company Limited
| Name | Category and Sector |
|---|---|
Takeda Manufacturing Austria AG
 Takeda Manufacturing Austria AG Manufactures and supplies vital medicines and medical devices | |
Takeda Manufacturing Austria AG
Takeda Manufacturing Austria AG Manufactures and supplies vital medicines and medical devices | |
Baxalta Innovations GmbH
 Baxalta Innovations GmbH Manufactures and supplies biopharmaceutical products | |
Baxalta Innovations GmbH
Baxalta Innovations GmbH Manufactures and supplies biopharmaceutical products | |
Takeda Pharmaceuticals International AG
 Takeda Pharmaceuticals International AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.14% | +5.07% | +23.27% | +23.93% | 50.76B | |
| +1.64% | +0.06% | +35.14% | +199.94% | 952B | |
| +2.61% | +1.14% | +47.63% | +19.92% | 492B | |
| -0.02% | -4.04% | +25.62% | +40.00% | 389B | |
| +0.50% | +5.22% | +29.29% | +18.53% | 363B | |
| -0.68% | +5.50% | +30.47% | +23.34% | 296B | |
| -1.21% | +2.57% | +10.02% | -1.69% | 274B | |
| -0.18% | +4.92% | +25.39% | +35.33% | 273B | |
| -0.62% | +9.33% | -38.17% | -17.02% | 264B | |
| -0.17% | +1.50% | +20.49% | +20.16% | 176B | |
| Average | +0.14% | +2.94% | +20.91% | +36.24% | 352.99B | |
| Weighted average by Cap. | +0.46% | +1.53% | +25.76% | +67.66% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4502 Stock
- Company Takeda Pharmaceutical Company Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition